Extracellular matrix metalloproteinase inducer (EMMPRIN) exhibits overexpression in various cancers and promotes cancer progression and metastasis via the interaction with its associated molecules. The scFv-M6-1B9 intrabody has a potential ability to reduce EMMPRIN cell surface expression. However, the subsequent effect of scFv-M6-1B9 intrabody-mediated EMMPRIN abatement on its related molecules, a3b1-integrin, MCT1, MMP-2 and MMP-9, is undefined. Our results demonstrated that the scFv-M6-1B9 intrabody efficiently decreased a3b1-integrin cell surface expression levels. In addition, intracellular accumulation of MCT1 and lactate were increased. These results lead to suppression of features characteristic for tumor progression, including cell migration, proliferation and invasion, in a colorectal cancer cell line (Caco-2) although there was no difference in MMP expression. Thus, EMMPRIN represents an attractive target molecule for the disruption of cancer proliferation and metastasis. An scFv-M6-1B9 intrabody-based approach could be relevant for cancer gene therapy.
INTRODUCTION

Colorectal cancer (CRC) is the most common cancer worldwide.
It is a significant cause of cancer-related deaths that mostly results from its poor prognosis and the advanced ability of cancer in metastasis to distant organs. 1, 2 Although there are several methods for cancer treatment, the successful treatment of metastatic CRC has been limited. Extracellular matrix metalloproteinase inducer (EMMPRIN), also known as CD147, is a potential candidate for cancer-targeted therapy because it has an important role in various processes in cancer progression. Many previous studies on the function of EMMPRIN have demonstrated its role in cell proliferation, invasion, metastasis, angiogenesis, glycolysis and multidrug-resistant (MDR) phenotypes mediated by many associated molecules. [3] [4] [5] It has been reported that EMMPRIN is associated with cell adhesion molecules, especially a6b1-integrin and a3b1-integrin, thus promoting invasion and metastasis. It was found that EMMPRIN and a3b1-integrin interaction activates focal adhesion kinase (FAK)-paxillin and FAK-phosphoinositide 3 kinase (FAK-PI3K)-Ca 2 þ signaling pathways, leading to the enhancement of metastasis of cancer cells. 6 EMMPRIN is also involved in tumor cell glycolysis through the proton-coupled monocarboxylate transporter (MCT) family, the key regulator of glycolysis and intracellular pH (pHi) homeostasis in cancer cells. EMMPRIN acts as a chaperone for MCT1 and facilitates MCT1 expression on the cell membrane leading to transportation of lactate that promotes cancer cell survival and disease progression. 7, 8 In addition, EMMPRIN also stimulates the production of matrix metalloproteinases (MMPs), a group of zinc-dependent enzymes with proteolytic activity. 3, 9, 10 Many studies have revealed that MMPs are highly expressed in various cancers and enhance the degradation of basement membranes and cell migration to distant organs. 9 There are several lines of evidence demonstrating that EMMPRIN can induce the expression of several MMPs, particularly MMP-2 and MMP-9. 11 We therefore hypothesize that EMMPRIN suppression affects its associated molecules, including a3b1-integrin, MCT1, MMP-2 and MMP-9 expression, and inhibits cell proliferation, migration and invasion.
Intracellular antibody or intrabody is an antibody molecule that functions inside a cell that blocks or modulates the function of a target protein or antigen. 12 Intrabody can achieve its effect in different cellular compartments by adding localization signal sequences. Intrabody with an endoplasmic reticulum (ER) retention signal retains the target protein in the ER and prevents the expression of the target protein on the cell surface. 13 Compared with RNAi-based approaches, intrabodies are more specific for an intracellular-targeted protein, have a longer half-life and are therefore more effective. 13, 14 Most intrabodies are derived from single-chain variable fragments (scFvs), which are expressed after gene transfer in target cells. Adenovirus vectors have been used for transfer of intrabody genes. 12 We previously showed that an adenovirus serotype 5 vector encoding scFv-M6-1B9 intrabody gene against EMMPRIN (Ad5-scFv-M6-1B9) efficiently decreased the surface expression of EMMPRIN on 293A cells 15 and HeLa cells. 16 It retained EMMPRIN in the ER with an ER retention signal (KDEL peptide), and intrabody-antigen complexes are considered to be degraded via different mechanisms. 17, 18 Serotype 5 Ad vectors infect cells through the coxsackie and adenovirus receptor (CAR). However, many human tumors often lack CAR, which makes them refractory to Ad5 infection. 19, 20 To overcome the disadvantages of Ad5-based vector, chimeric adenovirus 5/F35 (Ad5/F35), containing the fibers from Ad serotype 35, has been generated. These vectors use CD46, a membrane protein that is upregulated in most tumors as a receptor. 21, 22 In this study, we transferred the gene encoding scFv-M6-1B9 intrabody specific to EMMPRIN via a chimeric adenovirus 5/F35 (Ad5/F35-scFv-M6-1B9) into the CRC cell line Caco-2, which has a low expression level of CAR. EMMPRIN surface expression and a subsequent effect of scFv-M6-1B9 intrabody on related molecules, that is, a3b1-integrin, MCT1, MMP-2 and MMP-9, on Caco-2 cells were investigated.
MATERIALS AND METHODS
Cell culture
The human embryonic kidney cell line (293A) (Invitrogen, Grand Island, NY, USA) and the human CRC cell line (Caco-2) (a kind gift from Dr Samlee Mankhetkorn, Chiang Mai University, Chiang Mai, Thailand) were cultured in Dulbecco's modified Eagle's medium (DMEM) (Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS), penicillin (100 units ml À 1 ) and streptomycin (100 mg ml
). The cell lines were maintained in a humidified atmosphere of 5% CO 2 at 37 1C.
The generation of Ad5/F35-scFv-M6-1B9
For construction of the pAdE/F35-scFv-M6-1B9 vector, the PmeI-linearized and -purified pAdT-scFv-M6-1B9 vector (a shuttle vector plasmid) was co-electroporated with pAdEasy-1/35 (kindly provided by Prof. Andre Lieber, University of Washington, Seattle, WA, USA) in E. coli BJ5183. 15, 22 Ad5/F35-scFv-M6-1B9 and Ad5/F35-scFv-irrelevant were generated and propagated in 293A cells and purified as described elsewhere. 15, 23 All adenoviral titers were determined by agar plaque assay. Ad5/F35-expressing green fluorescent protein (Ad5/F35-GFP; kindly provided by Dr Saw-See Hong, University of Lyon 1, France). Ad5/F35-GFP and Ad5/-F35-scFv-irrelevant were used for transduction control.
Western immunoblotting analysis
Caco-2 cells were transduced with Ad5/F35-scFv-M6-1B9, Ad5/F35-scFvirrelevant or Ad5/F35-GFP at multiplicity of infection (MOI) of 100 p.f.u. per cell. After 48 h of transduction, the cells were harvested and lysed with lysis buffer (10 mM Tris-HCl pH 7.9, 150 mM NaCl, 1% NP-40, 1 Â Protease Inhibitor Cocktail Set I (Calbiochem, Billerica, MA, USA)). The total protein concentration was measured using the BCA assay. An equal amount of each protein sample was separated on a 12% SDS-PAGE and electroblotted onto polyvinylidene fluoride membrane. The membrane was then blocked with 5% non-fat dried milk in phosphate-buffered saline (PBS) for 1 h at room temperature and incubated with mouse anti-HA monoclonal antibody (mAb) (ABM, Richmond, British Columbia, Canada). After washing with 0.1% Tween-20 in PBS, peroxidase-conjugated goat anti-mouse immunoglobulin (Ig)G polyclonal antibody (pAb) (KPL, Gaithersburg, MD, USA) was added. After the washing step, the immunoreactive bands were then visualized by a chemiluminescent substrate detection system (Thermo Scientific, Waltham, MA, USA).
Confocal analysis
Caco-2 cells (5 Â 10 5 per well) were plated on sterilized cover glass in 6-well tissue culture plate and transduced at MOI 100 with Ad5/F35-scFv-M6-1B9, Ad5/F35-scFv-irrelevant or Ad5/F35-GFP for 48 h. The cells were then fixed with 4% paraformaldehyde in PBS and permeabilized with 0.1% Triton X-100. The fixed cells were then washed in PBS and blocked with 2% non-fat dried milk in PBS at room temperature for 30 min followed by incubation with mouse anti-HA mAb or rabbit anti-MCT1 pAb (Santacruz, Dallas, TX, USA). After washing, cells were then incubated with phycoerythrin-conjugated sheep anti-mouse Ig pAb (BD Pharmingen, Franklin Lakes, NJ, USA) or phycoerythrin-conjugated goat anti-rabbit IgG pAb (KPL). The cellular nuclei were counterstained by 4',6-diamidino-2-phenylindole (Invitrogen) and mounted in a Prolong Gold antifade (Vector Laboratories, Burlingame, CA, USA). Images were acquired using a confocal laser scanning microscope (NIS-Element version 4.0, Nikon, Melville, NY, USA).
Enzyme-linked immunosorbent assay
The binding activity of the scFv-M6-1B9 intrabody to EMMPRIN was evaluated by enzyme-linked immunosorbent assay. Avidin-carbonate/ bicarbonate buffer pH 8.6 (10 mg ml À 1 ) was coated on a microtiter plate and incubated overnight at 4 1C. The plates were then blocked with 2% bovine serum albumin (BSA) in PBS pH 7.2 at room temperature for 1 h. The wells were washed with 0.05% Tween-20 in PBS pH 7.2. After the washing step, 100 mg ml À 1 recombinant biotinylated CD147-BCCP or survivin-BCCP (SVV-BCCP, an irrelevant protein) fusion proteins in 2% BSA in PBS were added and incubated at room temperature for 1 h. The proteins extracted from Ad5/F35-scFv-M6-1B9-, Ad5/F35-scFv-irrelevant-or Ad5/F35-GFP-transduced cell lysates were diluted at 1:50 and 1:100. After washing, the protein lysates were added and incubated for 1 h at room temperature. The plate was washed with 0.05% Tween-20 in PBS pH 7.2 and followed by incubation with peroxidase-conjugated goat anti-HA mAb (Genscript, Piscataway, NJ, USA). The wells were then washed and followed by adding 100 ml of TMB substrate. The optical density at 450 nm was measured after adding 1 N HCl to stop the reaction. Two sets of triplicates were performed for each assay.
Flow cytometry analysis
Caco-2 cells were transduced with Ad5/F35-scFv-M6-1B9, Ad5/F35-scFvirrelevant or Ad5/F35-GFP at MOI of 100 and harvested after 48 h of transduction. Cells were then blocked with human AB serum for 30 min and incubated with mouse anti-CD147 mAb (clone M6-1B9) or mouse antia3b1-integrin mAb (Abcam, Cambridge, MA, USA). Phycoerythrin-conjugated sheep anti-mouse Ig pAb was used as a secondary antibody. For MCT1 staining, the cells were fixed and permeabilized with ice-cold methanol: acetone (1:1) at À 20 1C for 20 min and followed by washing with 1% BSA-PBS-NaN 3 . Cells were stained with rabbit anti-MCT1 pAb. Phycoerythrin-conjugated goat anti-rabbit IgG pAb was used as secondary antibody. Finally, the cells were washed with 1% BSA-PBS-NaN 3 , fixed with 1% paraformaldehyde in PBS and analyzed by flow cytometry.
Real-time quantitative reverse transcription PCR (qRT-PCR) analysis
Transduced Caco-2 cells with 100 MOI of Ad5/F35-scFv-M6-1B9, Ad5/F35-scFv-irrelevant or Ad5/F35-GFP for 48 h were harvested. Total RNA was extracted using a total RNA isolation NucleoSpin RNA II (Clontech, Mountain View, CA, USA) according to the instructions of the manufacturer. cDNA was synthesized from the isolated total RNA according to the RevertAid First Strand cDNA Synthesis Kit (Fermentas, Pittsburgh PA, USA). The primer sets for EMMPRIN, MMP-2, MMP-9, TIMP-1 and TIMP-2 are listed in Table 1 . The PCR for all genes was as follows: template initial denaturation (10 min at 95 1C), denaturation (15 s at 95 1C), annealing (30 s at 56 1C), extension (1 min at 60 1C) for 40 cycles and final extension (5 min at 60 1C). The amplified products were electrophoresed on a 1% agarose gel. Relative quantification was calculated from band intensities, which were normalized compared with GAPDH mRNA expression using Quantity One 1-D analysis software (Bio-Rad, Hercules, CA, USA). All experiments were performed in three independent trials. Table 1 . Sequence of primers used.
Primers
Sequences References
Abbreviations: EMMPRIN, extracellular matrix metalloproteinase inducer; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MMP, matrix metalloproteinase; TIMP, tissue inhibitors of the metalloproteinases.
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Nuclear magnetic resonance (NMR) for pHi analysis
Caco-2 cells (1 Â 10 6 per well) were seeded in a 6-well tissue culture plate for 24 h and transduced with Ad5/F35-scFv-M6-1B9 or Ad5/F35-scFvirrelevant (100 MOI). After 48 h of transduction, cells were washed twice with 500 ml of isotonic PBS and twice with 500 ml of deuterated-PBS buffer (D 2 O-PBS) (Sigma-Aldrich, St Louis, MO, USA). Then, 400 ml of D 2 O-PBS was added to the cells and transferred to an NMR tube. The intracellular lactate was performed using Bruker Avance 400 MHz NMR Spectrometer (Rheinstetten, Germany). MestRe-C 2.3a software (Santiago de Compostela, Spain) and OriginPro 8 software (Northampton, MA, USA) were used to acquire and analyze the spectra, respectively. These experiments were performed in three independent trials.
Cell proliferation assay
Caco-2 cells (1 Â 10 3 per well) were dispensed in a 96-well microplate and cultured for 24 h. The cells were transduced with 100 MOI of Ad5/F35-scFv-M6-1B9 or Ad5/F35-scFv-irrelevant for 0, 24 and 48 h. Cells were trypsinized and counted at the time of post transduction. For MTT assay, 15 ml of 5-mg ml À 1 MTT was added at posttransduction time and incubated at 37 1C. After 4 h of incubation, 200 ml of dimethyl sulfoxide was added to dissolve the dark blue crystals of MTT-formazan. The absorbance was then measured by an enzyme-linked immunosorbent assay plate reader using a test wavelength of 540 nm and a reference wavelength of 630 nm. All experiments were performed in triplicates of three independent trials.
Wound healing assay
Caco-2 cells (5 Â 10 5 per well) were cultured in a 6-well tissue culture plate for 24 h. The cells were transduced with 100 MOI of Ad5/F35-scFv-M6-1B9 or Ad5/F35-scFv-irrelevant for 24 h, and then a 200-ml micropipette tip was used to create a straight scratch as a wound. After scratching, the cell was gently washed with medium to remove the detached cells. The cells were cultured in fresh medium for 0 and 24 h, and an image was acquired at the reference point. The gap distance was evaluated and the percentage of wound closure was calculated. These experiments were performed in three independent trials.
Matrigel invasion assay
Caco-2 cells (1 Â 10 5 per well) were plated in a 24-well tissue culture plate. After 24 h of incubation, the cells were transduced with Ad5/F35-scFv-M6-1B9 or Ad5/F35-scFv-irrelevant at an MOI of 100 for 36 h. Then, the cells were trypsinized and replated on a Matrigel Invasion Chamber 24-well plate with an 8-mm pore size polyethylene terephthalate membrane (BD Biosciences, San Jose, CA, USA). Each lower compartment of the transwell contained 500 ml of 10% FBS in DMEM. The upper side of the insert was replaced with untransduced, Ad5/F35-scFv-M6-1B9 or Ad5/F35-scFvirrelevant-transduced cells (1 Â 10 5 ) in 500 ml serum-free medium and incubated for 0, 12 and 24 h. Noninvading cells in the upper compartment were gently removed with cotton swabs. The number of invading cells that can invade through the membrane into the lower compartment were determined and stained by Wright-Giemsa staining. These experiments were performed in three independent trials.
Gelatin zymography
Caco-2 cells (5 Â 10 5 per well) were grown in a 6-well tissue culture plate in a medium supplemented with 10% FBS. After 24 h of incubation, cells were transduced with Ad5/F35-scFv-M6-1B9 or Ad5/F35-scFv-irrelevant at MOI of 100 for 3 h. Cells were then washed twice and cultured in serum-free medium. After 48 h of incubation, the conditioned medium was collected and the protein was precipitated by ice-cold acetone method. The protein was mixed with non-reducing agent (0.3125 mM Tris-HCl, 10% SDS, 50% glycerol, 0.05% bromophenol blue, pH 6.8) and then separated by SDS-PAGE containing 1-mg ml À 1 gelatin type B (Sigma-Aldrich) in the resolving gel. After protein electrophoresis, the gel was analyzed for MMP activity. Briefly, the gel was washed twice in a washing solution (50 mM Tris, 5 mM CaCl 2 , 25% Triton X-100, pH 7.4) for 30 min at 37 1C. The gel was then incubated in a digestion buffer (50 mM Tris, 10 mM CaCl 2 , 150 mM NaCl, 0.02% NaN 3 , pH 7.4) with gentle rocking at 37 1C for 18 h. Finally, the gel was stained with 0.2% Coomassie brilliant blue. Gelatinase activity was shown by the clear zone of lysis against a blue background. The band intensities were visualized and analyzed using Image Quant TL software (GE Healthcare Life Science, Pittsburgh, PA, USA). These experiments were performed in three independent trials.
Statistical analysis
All results are represented as the mean± s.e.m. A comparison between groups was determined using one-way analysis of variance. Po0.05 was considered statistically significant. All calculations were performed using SPSS Statistics 17.0 software (Armonk, NY, USA).
RESULTS scFv-M6-1B9 intrabody expression and their specificity to EMMPRIN The transducibility of CRC cells by chimeric adenovirus encoding scFv-M6-1B9 intrabody was evaluated in Caco-2 cell line (Supplementary Figure S1 ). The produced scFv-M6-1B9 intrabody with an HA-tag (hemagglutinin) was detected by western immunoblotting using anti-HA mAbs. The expected band was revealed at B34 kDa and can be detected in the cell lysates from both Ad5/F35-scFv-M6-1B9-and Ad5/F35-scFv-irrelevant-transduced cells while in control, and Ad5/F35-GFP-transduced cells in the specific band were absent (Figure 1a) . Then we confirmed the localization of scFv-M6-1B9 intrabody by confocal laser scanning microscopy analysis. The results showed that the produced scFv-M6-1B9 intrabody harboring ER retention signal (KDEL peptide) was located in the cytoplasm (Figure 1b) . We also further evaluated the efficiency of scFv-M6-1B9 intrabody binding to EMMPRIN by enzyme-linked immunosorbent assay. The recombinant protein, CD147-BCCP, was used as target protein of the scFv-M6-1B9 intrabody. Several dilutions of scFv-M6-1B9 intrabodies extracted from cell lysates showed the positive signal with CD147-BCCP, whereas no signal was detected when SVV-BCCP was used as an irrelevant target protein (Figure 1c) . These results demonstrated that the produced scFv-M6-1B9 intrabody recognized specifically EMMPRIN.
scFv-M6-1B9 intrabody downregulated EMMPRIN cell surface expression To diminish EMMPRIN expression on Caco-2 cell surface, we transduced Ad5/F35-scFv-M6-1B9, Ad5/F35-scFv-irrelevant or Ad5/ F35-GFP at MOI of 100 p.f.u. per cell. After 48 h of transduction, we examined the expression of EMMPRIN on Caco-2 cell surface with anti-CD147 mAb (clone M6-1B9) by flow cytometry. The cells expressing scFv-M6-1B9 intrabodies exhibited a reduction in EMMPRIN expression of 50% compared with the cell control and transduction controls (Figure 2a ). This indicates that scFv-M6-1B9 intrabody efficiently reduced EMMPRIN cell surface levels.
To investigate whether intrabody in contrast to EMMPRIN could alter the EMMPRIN mRNA expression level, the total RNA from cell control or transduced Caco-2 cells with equal MOI of recombinant adenovirus harboring scFv-M6-1B9 (or scFv-irrelevant) were extracted after 48 h. EMMPRIN expression was assessed by qRT-PCR. The results showed no significant interference effect of EMMPRIN mRNA expression level in Caco-2 cells harboring scFv-M6-1B9 intrabody and transduction control. The quantification of the expression of EMMPRIN mRNA was relative to GAPDH mRNA (Figures 2b and c) . This result indicated that intrabody had a function at the protein level and no effect on EMMPRIN mRNA expression.
Diminishing of EMMPRIN cell surface expression via scFv-M6-1B9 intrabody influenced a3b1-integrin and MCT1 functions Subsequently, the effect of EMMPRIN suppression by scFv-M6-1B9 intrabodies on the expression of a3b1-integrin and MCT1 were investigated using anti-a3b1-integrin mAb and anti-MCT1 pAb staining, respectively. Using flow cytometry analysis, we found that a3b1-integrin cell surface expression was decreased in cells expressing scFv-M6-1B9 intrabodies compared with the other control groups (Figure 3 
Cells expressing scFv-M6-1B9 intrabodies had increased levels of intracellular MCT1 (Figure 4a) . The relative fluorescence intensity demonstrated a significantly higher level of MCT1 in Caco-2 cells expressing scFv-M6-1B9 intrabodies (Figure 4b) . The intracellular accumulation of MCT1 was confirmed by confocal laser scanning microscopy analysis (Figure 4c ). Then, we further determined whether EMMPRIN downregulation-induced intracellular MCT1 accumulation resulted in an increase of intracellular lactate levels and a decrease in pHi. The intracellular lactate level was monitored by NMR. scFv-M6-1B9 intrabody manipulated the progressive phenotypes of Caco-2 cells The influence of scFv-M6-1B9 intrabody expression on the phenotypic features that are associated with two key molecules, a3b1-integrin and MCT1, with tumor progression, such as cell migration, proliferation and invasion, was studied. We examined whether the scFv-M6-1B9 intrabody would inhibit the cell migration ability of Caco-2 cells using a wound healing assay. The cells were transduced with Ad5/F35-scFv-M6-1B9. After scratching to create a wound at 24 h post wounding, the wounds were 100% closed in the cell control. A similar result was observed with transduction control, indicating that chimeric adenovirus had no effect on the rate of wound closure (Figure 5a ). Interestingly, wound closure was significantly suppressed to 40% in transduced Caco-2 cells expressing scFv-M6-1B9 intrabody as compared with the other control groups (Po0.05) (Figure 5b ). This result indicated that scFv-M6-1B9 intrabody efficiently inhibited Caco-2 cell migration activity.
The effect of scFv-M6-1B9 intrabody on cell proliferation was examined with counting of cell number and MTT assay. Caco-2 cells were transduced with Ad5/F35-scFv-M6-1B9. After 24 h incubation, cell proliferation activity was measured compared with the other control groups. The result showed the reduction of cell number and significantly decreasing of MTT activity in Ad5/F35-scFv-M6-1B9-transduced cells (Figure 5c ). There was a significant reduction in cell proliferation (21.3%) for Ad5/F35-scFv-M6-1B9-transduced cells compared with Ad5/F35-scFvirrelevant transduction control (Po0.05) (Figure 5d ). This result implied that scFv-M6-1B9 intrabody abated Caco-2 cell proliferation.
Matrigel-coated invasion assay was used to study whether scFv-M6-1B9 intrabodies diminished the invasion capability of Caco-2 cells. The cells were transduced with Ad5/35-scFv-M6-1B9. The percentage of cell invasion was calculated and determined compared with the other control groups. The result demonstrated that Ad5/F35-scFv-irrelevant-and Ad5/F35-scFv-M6-1B9-transduced cells were able to pass through the Matrigel-coated Effect of scFv-M6-1B9 intrabody on MMP-2 and MMP-9 expression We further investigated whether scFv-M6-1B9 intrabodies had an effect on the MMP-2 and MMP-9 activities, which have a main function in cell invasion. Caco-2 cells were transduced with Ad5/ F35-scFv-M6-1B9 and the conditioned medium was analyzed after 48 h of incubation by gelatin zymography. The result showed no alteration of gelatinase activity of MMP-2 and MMP-9 between the supernatants from cell control, transduction control and Caco-2 cells expressing the scFv-M6-1B9 intrabody (Figure 6a ). We also confirmed the expression of MMP-2 and MMP-9 at the mRNA level by real-time qRT-PCR. There was no significant difference in the mRNA level of MMP-2 and MMP-9 between cells control, cells expressing scFv-irrelevant intrabody and cells expressing scFv-M6-1B9 intrabody. The quantification of the expression of MMP-2 and MMP-9 mRNAs was relative to GAPDH mRNA (Figures 6b and c) . We also further assessed the expression of tissue inhibitors of the metalloproteinases (TIMP)-1 and TIMP-2, endogenous inhibitor of MMPs. The quantification of the expression of TIMP-1 and TIMP-2 mRNAs relative to GAPDH mRNA was not altered as shown in Figures 6b and d . These data clarified that scFv-M6-1B9 intrabody mediating the diminishing of EMMPRIN cell surface had no effect on MMP-2 and MMP-9 expression. DISCUSSION EMMPRIN, a type 1 transmembrane glycoprotein composed of the extracellular region with two Ig-like domains, a transmembrane scFv-M6-1B9 intrabody affects EMMPRIN, a3b1-integrin in Caco-2 S Sangboonruang et al domain and a short cytoplasmic domain. 5, 24 The first extracellular Ig domain (EC I) is involved in MMPs induction, binding to counter-receptors for itself, 25 and association with integrins. 26 Wilson et al. revealed that a cytoplasmic domain of EMMPRIN binds to two molecules of MCT1. 27 It also possesses a high expression in many types of cancer and has a crucial role in cancer progression and metastasis via interaction with other proteins. 4 Previous reports have focused on the downregulation of EMMPRIN via gene silencing and its effect on multistep processes of tumor growth and metastasis. [28] [29] [30] In this context, scFv-M6-1B9 intrabody-exhibited biological activity in its target, EMMPRIN, was delivered to the CRC cell line, Caco-2, by the chimeric Ad5/F35. Ad5/F35-scFv-M6-1B9 was used to overcome the limitation of Ad5 refractory cell transduction in the low CAR-expressing cells. EMMPRIN reduction on the cell surface was found in Caco-2 cells expressing the scFv-M6-1B9 intrabody. Because EMMPRIN expression was diminished, its subsequent effects on the key associated molecules, such as a3b1-integrin and MCT1, were further investigated. The scFv-M6-1B9 intrabody mediated EMMPRIN suppression, reducing the expression level of a3b1-integrin on Caco-2 cell surface. This indicated the interaction of EMMPRIN and a3b1-integrin, and the results agreed with a previous study stating that EMMPRIN complexes with a3b1-integrin and upregulates the level of a3b1-integrin. 6, 26 EMMPRIN silencing by a small interfering RNA decreased the expression of MCT1 and MCT4, and their co-localization with EMMPRIN 4 and also diminished glycolysis rate and many progression processes. 30 This disturbance of EMMPRIN and MCT1 co-expression can induce cell death and impairment of pHi homeostasis. 4, 8, 30 An interesting finding from our results is the ability of scFv-M6-1B9 intrabody in not only suppressing the EMMPRIN expression but also in increasing the expression of MCT1 inside the Caco-2 cells. MCT1 and MCT4 have been shown to interact specifically with EMMPRIN. This interaction facilitates the proper expression of MCT on cell surface. 7, 31, 32 As a result of the reduction of EMMPRIN on cell surface, consequently, the interaction of MCT1 with their chaperone could be interfered at the cell surface. Hence, the MCT1 was accumulated and caused a high level of intracellular lactate resulting in pH of the cytosol to decrease. Thus, the decline of EMMPRIN translocation to cell surface is an important requirement for the expression of MCT1. These effects obstructed lactate efflux and induced the acidic microenvironment, leading to the impairment of tumor cell glycolysis and reduction in cell viability.
Owing to the reduction of EMMPRIN expression via intrabodyaltered a3b1-integrin and MCT1 expression, the in vitro cancer progression, for example, cell migration, cell proliferation and cell invasion, was also suppressed in Caco-2 cells. Likewise, another study reported the correlation between EMMPRIN expression and cell proliferation. EMMPRIN gene silencing resulted in the decreased proliferation and migration of Jurkat cells, 28 human colorectal adenocarcinoma cell line (HT-29) 33 and gastric cancer cell line (SGC7901). 34 Several studies investigated the mechanisms that support a crucial role of EMMPRIN in cell proliferation and scFv-M6-1B9 intrabody affects EMMPRIN, a3b1-integrin in Caco-2 S Sangboonruang et al migration. The first mechanism involved in extracellular signalregulated kinase (ERK), a member of the mitogen-activated protein kinases family. It maintains diverse cellular function including cell proliferation or apoptosis by regulating the activity of anti-and pro-apoptotic transcription factors. 35, 36 Reduction of EMMPRIN correlated with the activities of the phosphorylation of the ERK1/2 in SGC7901 cells. 34 Thus, downregulation of ERK1/2 activity can inhibit cell survival. The second mechanism might be taken in the integrin signaling pathways. Integrins act as receptors for extracellular matrix proteins and intracellular signal transduction in the processes of cell adhesion, proliferation, differentiation, apoptosis and tumor progression. In previous studies, EMMPRIN was found to be associated with integrins. 26, 37, 38 Blocking the interaction of EMMPRIN with the b1-integrin subunit by EMMPRIN-specific small hairpin RNA (sh-CD147) and arginine-glycine-aspartic acid (RGD) peptide containing the RGD motif peptide inactivated the downstream FAK pathway resulting in a rearranged actin cytoskeleton. Simultaneously, the reduction of cell adhesion, invasion and MMPs secretion of human hepatoma cells. 6 In addition, the elevated of EMMPRIN expression stimulates vascular endothelial growth factor production of cancer cell involves in the PI3K-Akt signaling pathway. 39 Several studies have also reported defective EMMPRIN and MCT1 interaction by EMMPRIN mRNA knocking down or blocking EMMPRIN with monoclonal antibody-inhibited cell viability, migration, proliferation invasiveness and vascular endothelial growth factor production. 4, 5, 8, 30 Therefore, the influence of EMMPRIN downregulation via scFv-M6-1B9 intrabody-exhibited multipotency of the two key molecules, a3b1-integrin and MCT1, may regulate the signal transduction pathways that are involved in cancer progression and metastasis.
Because EMMPRIN exhibited a potential in inducing MMP production, particularly MMP-2 and MMP-9, 11, 40 and EMMPRIN downregulated Caco-2 cells via scFv-M6-1B9 intrabody, there was a decreased migration and invasion. Moreover, MMP-2 and MMP-9 activities were also upregulated by a3b1-integrin and promoted the invasive human hepatoma cell migration on laminin-5. 41 In this study, however, no alterations of MMP-2 and MMP-9 expression in both gelatinase activity and mRNA level were shown. This is consistent with our previous study in HeLa cells that showed no difference in MMP-2 and MMP-9 activities. 16 Importantly, the proteolytic activity of MMPs can be also regulated by the endogenous TIMPs. 42, 43 To clarify, we further analyzed the expression of TIMP-1 and TIMP-2 and the endogenous tissue inhibitors of MMPs, 44 and the data supported that the functional properties of MMPs and TIMPs are still balanced and scFv-M6-1B9 intrabodies could not influence the enzyme-inhibitor interaction. Moreover, of the several MMPs involved in the extracellular matrix degradation, not only MMP-2 and MMP-9 45 but also the reversion-inducing cysteine-rich protein with Kazal motifs also regulates the activity of MMP-2, MMP-9 and membrane type 1-MMP in many cancer cell lines. 42, 46 Besides MMPs, the serine protease urokinase plasminogen activator is also an important factor in promoting cancer cell invasion and metastasis. 47 Evidence has demonstrated that EMMPRIN can upregulate the expression of urokinase plasminogen activator and induce its proteolytic activity in cancer progression. 48, 49 scFv-M6-1B9 intrabody affects EMMPRIN, a3b1-integrin in Caco-2 S Sangboonruang et al From this study, EMMPRIN represents its effectiveness and could be a candidate target molecule for cancer treatment, especially in the metastatic stage. Reduction of EMMPRIN shows the multipotent effects as it can interact and regulate the function of various associated molecules. In the present study, we utilized intrabody technology to express an intrabody-specific EMMPRIN and block the translocation of EMMPRIN on the cell surface membrane. The intrabody binds to the specific active domains of the target protein at the posttranslational level. 13, 50 Its effect is superior to that of the RNAi technique, one of the gene therapy approaches that is commonly used in gene knockdown. 51 The RNAi technique has many nonspecific effects, particularly in the case of point mutation; 13 thus, it might not be appropriate for cancer gene therapy. Therefore, scFv-M6-1B9 intrabodies strengthen an appropriate approach for an alternative treatment or act as a combination treatment with traditional methods.
Moreover, the scFv-M6-1B9 intrabodies expressed inside the cells required the gene transfer technique using an adenoviral vector system. Our work demonstrated the usefulness of an adenoviral vector system in transferring intrabodies into HeLa cells to improve our intrabody gene transfer efficiency. 16 Furthermore, switching Ad fibers from serotype 5-35, which uses CD46 as a receptor, increased the transduction efficiency and showed more advantages than Ad5 vector for gene therapy. Previously, modification of Ad5-based vector with Ad35 tropism also improved gene transfer in primary malignant hematopoietic cells, which were refractory to the Ad5 vector. 22 It has been reported that Ad5F35/MKp-E1 greatly enhanced gene transfer when compared with Ad5/MKp-E1 and is suitable for bladder cancer cells with low CAR expression. 52 For the human primary cell culture study, the modified Ad5/F35 containing Tat-PTD also showed more transduction capacity than Ad5-based vector. 53 Ni et al. 54 constructed Ad5/F35-bGal and showed better safety than Ad5-bGal, a first-generation Ad5 vector in baboons. They also further studied the toxicity after intravenous injection with Ad5/ 35.IR-E1A/TRAIL, which demonstrated no signs of illness in this animal. In this study, the chimeric Ad5/F35 was also used to overcome the limitation of transduction into the cells that expressed a low level of CAR receptors. However, the application of an adenoviral gene transfer system should include several precautions for the inflammatory response and immune response in preexisting patients with immune system problems. [54] [55] [56] We suggest that this method is proper for solid cancer or local treatment, transplants of colon tumors into a mouse could be utilized as an experimental model in the future for studying the efficacy of scFv-M6-1B9 intrabodies.
In summary, we have assessed for the first time the effect of this intrabody on EMMPRIN and its associated molecules in Caco-2 cells. Our findings demonstrated that scFv-M6-1B9 intrabodies not only diminished EMMPRIN cell surface expression but also Figure 6 . The scFv-M6-1B9 intrabody had no effect on MMP-2 and MMP-9 protein and mRNA levels. scFv-M6-1B9 intrabody affects EMMPRIN, a3b1-integrin in Caco-2 S Sangboonruang et al exhibited an efficient ability to reduce a3b1-integrin cell surface expression and to increase MCT1 intracellular accumulation. These effects led to the reduction of progressive phenotypes in cancer, such as cell proliferation, migration and invasion. This present study suggests that EMMPRIN, a potential therapeutic target for cancer treatment, is an important protein in tumor progression. Thus, the scFv-M6-1B9 intrabody might be used as an alternative approach for cancer gene therapy.
